BACKGROUND: This study assessed the clinical sensitivity of three fully automated, human immunodeficiency virus (HIV), hepatitis C virus (HCV), and hepatitis B virus (HBV) triplex nucleic acid test (NAT) assays by individual donation (ID-NAT) and at operational minipool (MP-NAT) sizes used worldwide. STUDY DESIGN AND METHODS: MPX, Ultrio, and Ultrio Plus were used to test 2222 pedigreed, marker-positive samples with varying viral loads, each from a unique US blood donor. NAT-positive, seronegative yield samples (16 HBV, 156 HCV, and 23 HIV) were tested in replicates of three; undiluted; and in 1:6, 1:8, and 1:16 dilutions (MP6, MP8, and MP16), simulating various MP sizes. Seropositive samples (1276 HBV, 488 HCV, and 263 HIV) were tested by ID-NAT in singlet. RESULTS: MPX-MP6 and Ultrio Plus-MP16 had equivalent HCV sensitivity. Although Ultrio Plus-MP16 for HIV trended toward lesser sensitivity, this was not corroborated in a large substudy of low-viral-load samples in which Ultrio Plus-MP8/MP16 showed 100% reactivity. MPX-ID and Ultrio Plus-ID HBV clinical sensitivity were identical, but MPX-MP6 was significantly more sensitive than Ultrio Plus-MP16; the differential yield projected to one HBV NAT yield per 4.72 million US donations. Ultrio Plus HBV sensitivity did not increase at MP8 versus MP16. Ultrio Plus versus Ultrio sensitivity was significantly increased in HBV-infected donors with early acute, late acute or chronic, and occult infections. No difference in sensitivity was noted for any virus for MPX-MP6 versus Ultrio Plus-ID. CONCLUSIONS: Our data support US donation screening with MPX-MP6 or Ultrio Plus-MP16 since the HBV DNA detection of Ultrio Plus was significantly enhanced (vs. Ultrio) without compromising HIV or HCV RNA detection.
BACKGROUND: This study assessed the clinical sensitivity of three fully automated, human immunodeficiency virus (HIV), hepatitis C virus (HCV), and hepatitis B virus (HBV) triplex nucleic acid test (NAT) assays by individual donation (ID-NAT) and at operational minipool (MP-NAT) sizes used worldwide. STUDY DESIGN AND METHODS: MPX, Ultrio, and Ultrio Plus were used to test 2222 pedigreed, marker-positive samples with varying viral loads, each from a unique US blood donor. NAT-positive, seronegative yield samples (16 HBV, 156 HCV, and 23 HIV) were tested in replicates of three; undiluted; and in 1:6, 1:8, and 1:16 dilutions (MP6, MP8, and MP16), simulating various MP sizes. Seropositive samples (1276 HBV, 488 HCV, and 263 HIV) were tested by ID-NAT in singlet. RESULTS: MPX-MP6 and Ultrio Plus-MP16 had equivalent HCV sensitivity. Although Ultrio Plus-MP16 for HIV trended toward lesser sensitivity, this was not corroborated in a large substudy of low-viral-load samples in which Ultrio Plus-MP8/MP16 showed 100% reactivity. MPX-ID and Ultrio Plus-ID HBV clinical sensitivity were identical, but MPX-MP6 was significantly more sensitive than Ultrio Plus-MP16; the differential yield projected to one HBV NAT yield per 4.72 million US donations. Ultrio Plus HBV sensitivity did not increase at MP8 versus MP16. Ultrio Plus versus Ultrio sensitivity was significantly increased in HBV-infected donors with early acute, late acute or chronic, and occult infections. No difference in sensitivity was noted for any virus for MPX-MP6 versus Ultrio Plus-ID. CONCLUSIONS: Our data support US donation screening with MPX-MP6 or Ultrio Plus-MP16 since the HBV DNA detection of Ultrio Plus was significantly enhanced (vs. Ultrio) without compromising HIV or HCV RNA detection.
Authors: Sumathi Ramachandran; Jamel A Groves; Guo-Liang Xia; Paula Saá; Edward P Notari; Jan Drobeniuc; Amanda Poe; Natasha Khudyakov; Sarah F Schillie; Trudy V Murphy; Saleem Kamili; Chong-Gee Teo; Roger Y Dodd; Yury E Khudyakov; Susan L Stramer Journal: Transfusion Date: 2018-11-30 Impact factor: 3.157
Authors: Mohammad Irshad; Priyanka Gupta; Dhananjay Singh Mankotia; Mohammad Ahmad Ansari Journal: World J Gastroenterol Date: 2016-05-28 Impact factor: 5.742
Authors: Peijie Hou; Joshua M Tebbs; Dewei Wang; Christopher S McMahan; Christopher R Bilder Journal: Biostatistics Date: 2020-07-01 Impact factor: 5.899
Authors: Thomas A Rasmussen; Martin Tolstrup; Holger Jon Møller; Christel R Brinkmann; Rikke Olesen; Christian Erikstrup; Alex L Laursen; Lars Østergaard; Ole S Søgaard Journal: Open Forum Infect Dis Date: 2015-03-30 Impact factor: 3.835
Authors: Ole S Søgaard; Mette E Graversen; Steffen Leth; Rikke Olesen; Christel R Brinkmann; Sara K Nissen; Anne Sofie Kjaer; Mariane H Schleimann; Paul W Denton; William J Hey-Cunningham; Kersten K Koelsch; Giuseppe Pantaleo; Kim Krogsgaard; Maja Sommerfelt; Remi Fromentin; Nicolas Chomont; Thomas A Rasmussen; Lars Østergaard; Martin Tolstrup Journal: PLoS Pathog Date: 2015-09-17 Impact factor: 6.823
Authors: Dennis G Fisher; Kristen L Hess; Erlyana Erlyana; Grace L Reynolds; Catherine A Cummins; Todd A Alonzo Journal: Open Forum Infect Dis Date: 2015-07-07 Impact factor: 3.835